Skip to Content

IMvigor130: Final overall survival (OS) analysis of atezolizumab with/without chemotherapy

IMvigor130 is a randomized phase III study investigating efficacy of first-line treatment with atezolizumab monotherapy versus atezolizumab in combination with chemotherapy versus chemotherapy monotherapy for advanced or metastatic urothelial carcinoma (mUC). Let Professor Aristotle Bamias present the exciting results presented at ASCO GU 2023 in this MEDtalk.

Aristotle Bamias

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top